Takeda Pharmaceutical Co. Ltd. 4502
TSE · Japan · Health Technology
¥5,731.00-49.00 (-0.85%)
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Takeda Pharmaceutical has delivered a strong multi year run, and recent drug trial headlines now put a sharper spotlight on whether the current share price lines up with its sales base. For investors watching Takeda stock today, the core issue is how that performance and pipeline story stack up against what the business is actually generating in revenue. Takeda shares are up 120.5% over 5 years, which raises the question of how much of that gain is supported by the company’s sales...
WASHINGTON & TOKYO, October 01, 2026--Corus International announced it has received a $6.4 million grant from Takeda Pharmaceutical Company Limited to help reduce climate-related health risks in Nepal. Corus was selected as part of Takeda’s 2026 Global Corporate Social Responsibility (CSR) program. The company issued a press release announcing all the awardees and the scope of its program.
Takeda Pharmaceutical recently reported Phase 3 data showing that its investigational oral TYK2 inhibitor, zasocitinib (TAK-279), achieved statistically superior complete skin clearance versus deucravacitinib and outperformed apremilast in adults with moderate-to-severe plaque psoriasis, with results presented at the 2026 European Academy of Dermatology & Venereology Congress. A particularly important finding is that zasocitinib delivered more than 2.5 times as many patients with complete...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.